JAMESBURG, N.J., June 16 /PRNewswire/ -- Phytomedics Inc., a clinical stage biopharmaceutical company developing a novel portfolio of drugs and consumer products solely derived from plant sources, today announced that Dr. Laurie Smaldone, MD, President and Chief Executive Officer, will deliver an investor presentation at the 2010 New York Venture Summit, on June 17th, 2010, held at New York's Hotel Pennsylvania, 401 Seventh Avenue, New York, N.Y.
Dr. Smaldone's presentation will take place during the Round III Life Sciences presentations beginning at 1:50 pm.
Her presentation will provide a corporate overview and highlight the clinical progress of the company's lead drug candidate, PMI-001, a novel, oral, disease-modifying, non-steroidal, natural product alternative to injectable biologicals in patients with RA.
Three U.S. based, FDA-approved clinical trials, have confirmed biological like efficacy of this botanical drug candidate as a stand-alone therapy in reducing signs and symptoms of RA at all American College of Rheumatology (ACR) endpoints, a rapid onset of action and, the ability to halt joint erosions and narrowing with an acceptable side effect profile. Combined with the fact that this natural botanical drug product is delivered as an oral dosage form, and has no steroid like side effects, makes PMI-001 truly is a game changing therapeutic opportunity in RA, as well as in the wider AA space.
About Phytomedics Inc.
Phytomedics, Inc. is a clinical stage biopharmaceutical company with a novel portfolio of drugs and consumer products solely derived from pl
|SOURCE Phytomedics Inc.|
Copyright©2010 PR Newswire.
All rights reserved